Search Results - Therapeutic

38 Results Sort By:
Cyclic Peptide Inhibitors of Lysine-Specific Demethylase 1- Sickle Cell Disease
Cyclic Peptide Inhibitors of Lysine-Specific Demethylase 1 (LSD1) for Sickle Cell Disease Technology: Researchers at MUSC have used a ligand-based approach to design and synthesize a series of cyclic peptides that are effective inhibitors of LSD1, and have greater stability to proteolytic degradation than their linear homologues. For example, cycli...
Published: 9/13/2017   |   Inventor(s):  
Keywords(s):  
Category(s): Therapeutic
Mitochondrial targeted HDAC inhibitors for the treatment of heart failure and related diseases and disorders (MitoDACs)
Mitochondrial targeted HDAC inhibitors for the treatment of heart failure and related diseases and disorders (MitoDACs)Technology: Researchers at MUSC have discovered HDAC1 is present in the adult cardiac myocyte mitochondria. A series of HDAC1 inhibitors that target mitochondria have been made (MitoDACs). One of the analog, LL-66, localizes to the...
Published: 8/22/2017   |   Inventor(s): Donald Menick, Chung-Jen (James) Chou, Daniel Herr, Xiaoyang Li
Keywords(s):  
Category(s): Therapeutic
Pharmaceuticaly Modified T cells for Adoptive Cell Therapy Against Cancer
Inventors have found that treatment of tumor-reactive human T cells with drugs that co-modulate β-catenin and PI3Kδ enhances their antitumor capacity, especially their ability to exert a long-term immune response against cancer. Th17 cells inhibited of both pathways expressed less RORγt, which, in turn, reduced their ability to sec...
Published: 7/10/2017   |   Inventor(s): Chrystal Paulos, Kinga Majchrzak, Jacob Bowers
Keywords(s):  
Category(s): Therapeutic
Antifibrotic effects of oxetanyl sulfoxides
Currently, there are only two approved therapies for Idiopathic Pulmonary Fibrosis (IPF), pirfenidone and nintedanib, which are minimally effective at slowing the disease. These treatments are not effective at all in halting or reversing the progression of IPF. Therefore, there remains a great need for more effective therapies. Researchers at MUSC ...
Published: 6/14/2017   |   Inventor(s): Carol Feghali-Bostwick, Peter Wipf
Keywords(s):  
Category(s): Therapeutic
Delivery of chemotherapeutics to brain tumors
Brain cancer is a life-threatening disease with a poor prognosis. This includes Glioblastoma Multiform (GBM), which has a standard treatment of surgical resection, radiation therapy and concurrent chemotherapy with temozolomide (TMZ). The median survival is 14 months because surgeons are unable to completely remove GBM, radiation does not completel...
Published: 5/18/2017   |   Inventor(s): Ann-Marie Broome, Suraj Dixit, Amy-Lee Bredlau
Keywords(s):  
Category(s): Therapeutic
Tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCR)
Pathologies associated with Luteinizing hormone-releasing hormone LHRH include a number of cancers, prostate hyperplasia, endometriosis, uterine fibroids and polycystic ovary syndrome. Analogues for LHRH have been developed to treat gynecological disorders and cancers, including leuprolide and triptorelin. However, agonists of LHRH lead to total ph...
Published: 5/16/2017   |   Inventor(s): Klaus Paulini, Matthias Gerlach, Eckhard Guenther, Emmanuel Polymeropoulos, Silke Baasner, Peter Schmidt, Ronald Kuhne, Arvid Soderhall
Keywords(s):  
Category(s): Therapeutic
CD38 mediated metabolic axis in anti-tumor T cell immunotherapy
Tumor-induced immune suppression constitutes an important barrier for effective anti-tumor immunity and immunotherapy in cancer. MUSC inventors’ preliminary data suggests that targeting CD38 expression on anti-tumor T cells result in decreased NAD+ levels, which has been shown to result in increased longevity and epigenetically regulating th...
Published: 5/12/2017   |   Inventor(s): Shikhar Mehrotra, Shilpak Chatterjee
Keywords(s):  
Category(s): Therapeutic
Improving Tumor Suppression Effects of Cisplatin Utilizing a HPV Derived Peptide for Head and Neck Cancers
Inventors found that human papillomavirus (HPV) activates a specific protein called E2F5 to improve cell death in HPV(+) head and neck squamous cell carcinoma (HNSCC) cells and tumors in culture and in animals. Using molecular, pharmacologic and genetic tools, the inventors have shown that HPV early protein 7 (E7) enhances ceramide-mediated lethal ...
Published: 4/11/2017   |   Inventor(s): Besim Ogretmen, Raquelia Thomas, Natalia Oleinik
Keywords(s):  
Category(s): Therapeutic
LSD1 Protein Inhibitors as Fetal Hemoglobin Inducers for Sickle Cell Disease
Researchers at MUSC have identified several potential inhibitors of lysine-specific demethylase 1 (LSD1) utilizing a virtual screen, and found compounds that fit the LSD1 active site in silico. Researchers have synthesized these molecules and evaluated them as LSD1 inhibitors, and several compounds inhibit the enzyme with Ki values in the mid-to up...
Published: 4/4/2017   |   Inventor(s): Patrick Woster, Craig Kutz
Keywords(s):  
Category(s): Therapeutic
Application of GARP antibodies and fusion proteins in cancer, inflammatory and immune conditions
Researchers at MUSC have demonstrated that GARP is a novel oncogene due to its cancer-intrinsic roles in promoting invasion and metastasis, as well as its cancer-extrinsic roles in inducing immune tolerance. Administration of a GARP-specific mAb limited metastasis and resulted in an effective cancer therapy in a mouse model of breast cancer (Fig 1)...
Published: 2/1/2017   |   Inventor(s): Zihai Li
Keywords(s): cancer, immune, therapeutic
Category(s): Therapeutic
1 2 3 4 
© 2017. All Rights Reserved. Powered by Inteum